Answers are grounded in this paper and cite their sources.
Intravenous administration of macrophage-targeted glucocerebrosidase produces objective clinical improvement in patients with type 1 Gaucher's disease. The hematologic and visceral responses to enzyme replacement develop more rapidly than the skeletal response.
No takes yet. Share an insight, caveat, or question.
Barton et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: